AgingResearch.NewsJoin free

HuaDong Pharmaceutical

CompanyChina

HuaDong Pharmaceutical develops 2 assets, the furthest in phase 3 (HDG1901 in type 2 diabetes). Mostly peptide and small molecule acting on GLP1R; based in China.

2
Assets
Furthest stage
Phase 3
0
Trials
1
Signal

Pipeline

2

  • HDG1901

    GLP-1 receptor agonist biosimilar stimulating insulin release and regulating glucose.

    Phase 3, Peptide, GLP1R, type 2 diabetes

  • HDM1002

    Oral small-molecule glucagon-like peptide-1 receptor agonist stimulating glucose-dependent insulin secretion.

    Phase 3, Small molecule, GLP1R, type 2 diabetes, obesity

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Signals10
  • Similar companies6

Papers

Intelligence